Details of the Drug

General Information of Drug (ID: DM3M2BX)

Drug Name

VLX-1005

Synonyms

ML355; 1532593-30-8; ML355 free base; ML-355; VLX-1005; N-(1,3-benzothiazol-2-yl)-4-[(2-hydroxy-3-methoxyphenyl)methylamino]benzenesulfonamide; JKU4XCC48Y; CHEMBL3113165; ML 355; N-(1,3-benzothiazol-2-yl)-4-{[(2-hydroxy-3-methoxyphenyl)methyl]amino}benzene-1-sulfonamide; N-(benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide; Benzenesulfonamide, N-2-benzothiazolyl-4-(((2-hydroxy-3-methoxyphenyl)methyl)amino)-; N-2-Benzothiazolyl-4-(((2-hydroxy-3-methoxyphenyl)methyl)amino)benzenesulfonamide; N-2-benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]-benzenesulfonamide; NCGC00263773-03; N-2-Benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]benzenesulfonamide; ZR5; UNII-JKU4XCC48Y; GTPL8752; SCHEMBL16646023; VLX1005; CHEBI:195557; BCP28954; EX-A1987; VLX 1005; BDBM50447175; s6557; AKOS030526578; CS-3351; NCGC00263773-01; NCGC00263773-18; AC-36858; BS-15552; HY-12341; A908037; Q27087172; N-(1,3-benzothiazol-2-yl)-4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonamide; N-(Benzo[d]thiazol-2-yl)-4-(2-hydroxy-3-methoxybenzylamino)benzenesulfonamide; ML-355; ML-355;N-(Benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Heparin-induced thrombocytopenia	3B64.12	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C21H19N3O4S2
Canonical SMILES: COC1=CC=CC(=C1O)CNC2=CC=C(C=C2)S(=O)(=O)NC3=NC4=CC=CC=C4S3
InChI: InChI=1S/C21H19N3O4S2/c1-28-18-7-4-5-14(20(18)25)13-22-15-9-11-16(12-10-15)30(26,27)24-21-23-17-6-2-3-8-19(17)29-21/h2-12,22,25H,13H2,1H3,(H,23,24)
InChIKey: OWHBVKBNNRYMIN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 70701426
TTD ID: DD1E6R

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)	TTQ4QQH	LX12B_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05785819) A Randomized, Double-Blind, Phase 2 Pilot Study of VLX-1005 Versus Placebo in Participants With Suspected Heparin Induced Thrombocytopenia Treated With Background Standard of Care. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Veralox Therapeutics